0J9P Panoramica delle azioni Incyte Corporation, azienda biofarmaceutica, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di farmaci per l'ematologia/oncologia, l'infiammazione e l'autoimmunità negli Stati Uniti e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Incyte Corporation Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Incyte Prezzi storici delle azioni Prezzo attuale dell'azione US$69.00 Massimo di 52 settimane US$83.54 Minimo di 52 settimane US$50.02 Beta 0.70 Variazione di 1 mese -4.21% Variazione a 3 mesi 3.57% Variazione di 1 anno 3.36% Variazione a 3 anni -4.32% Variazione a 5 anni -23.47% Variazione dall'IPO -27.76%
Notizie e aggiornamenti recenti
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer Dec 08
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs Nov 19
Third quarter 2024 earnings released: EPS: US$0.55 (vs US$0.76 in 3Q 2023) Oct 29
Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024 Oct 08
Insufficient new directors Oct 01 Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer Vedi altri aggiornamenti
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer Dec 08
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs Nov 19
Third quarter 2024 earnings released: EPS: US$0.55 (vs US$0.76 in 3Q 2023) Oct 29
Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024 Oct 08
Insufficient new directors Oct 01 Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma Aug 16
Executive VP & Chief Medical Officer recently sold US$704k worth of stock Aug 15
Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) Aug 15
Second quarter 2024 earnings released: US$2.04 loss per share (vs US$0.91 profit in 2Q 2023) Jul 31
Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock Jul 30
Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024 Jul 10
Executive VP & GM of North America recently sold US$1.1m worth of stock Jun 15
Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders. Jun 01 Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares. May 16
Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares. May 14
First quarter 2024 earnings released: EPS: US$0.76 (vs US$0.097 in 1Q 2023) May 01
Incyte Corporation, Annual General Meeting, Jun 12, 2024 May 01
Incyte Corporation Maintains Earnings Guidance for 2024 Apr 30
Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million. Apr 23
Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024 Apr 12
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS) Mar 11
Incyte Corporation Provides Earnings Guidance for 2024 Feb 14
Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022) Feb 13
Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024 Jan 24
Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease Dec 11
Incyte Corporation Provides Earning Guidance for the Full Year 2023 Nov 01
Third quarter 2023 earnings released: EPS: US$0.76 (vs US$0.51 in 3Q 2022) Oct 31 Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo Oct 12
Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023 Oct 11
Incyte Corporation Announces Executive Changes, Effective November 1, 2023 Sep 14
Executive VP & Chief Medical Officer recently sold US$1.4m worth of stock Aug 06
Incyte Corporation Revises Earnings Guidance for the Year 2023 Aug 02
Second quarter 2023 earnings released: EPS: US$0.91 (vs US$0.73 in 2Q 2022) Aug 02
Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease Jul 25 Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023
Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023 May 09
First quarter 2023 earnings released: EPS: US$0.097 (vs US$0.17 in 1Q 2022) May 03
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa Feb 11 Incyte Corporation Provides Earnings Guidance for the Year 2023
Full year 2022 earnings released: EPS: US$1.53 (vs US$4.30 in FY 2021) Feb 08
Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023 Jan 18
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis Dec 13
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology Dec 06
Third quarter 2022 earnings released: EPS: US$0.51 (vs US$0.82 in 3Q 2021) Nov 02
Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine Oct 20
Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022 Oct 12
Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors Oct 05
Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion. Oct 04
Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement Aug 27
Second quarter 2022 earnings released: EPS: US$0.73 (vs US$0.68 in 2Q 2021) Aug 03
Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022 Aug 03
Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo Jul 19
Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022 Jul 13
FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata Jun 14
Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa) May 21
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 May 12
Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease May 05
First quarter 2022 earnings released: EPS: US$0.17 (vs US$0.24 in 1Q 2021) May 03
Incyte Corporation, Annual General Meeting, Jun 15, 2022 May 02
Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer Apr 23
Incyte Corporation to Report Q1, 2022 Results on May 03, 2022 Apr 13
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 09
Incyte Corporation Provides Revenue Guidance for the Full Year 2022 Feb 09
Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo Dec 15 MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.069 loss in 3Q 2020) Nov 03
Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million. Sep 29 Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD) Sep 23
Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults Sep 20
Calithera Biosciences, Inc. Enters into A Settlement Agreement and Release with Incyte Corporation Sep 19
Incyte Announces Health Canada Approval of Minjuvi® in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Aug 25
Eli Lilly and Company and Incyte Announce Results from an Additional Cohort of 101 Adult Patients from the COV-Barrier Trial Aug 05
Second quarter 2021 earnings released: EPS US$0.68 (vs US$1.33 in 2Q 2020) Aug 04
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease Jul 15
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Jun 26
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis Jun 12
Incyte Corporation Announces U.S. Food and Drug Administration Extends sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease Jun 09
Incyte and MorphoSys US, Inc. Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL Jun 05
Incyte Corporation Announces Positive Primary Analysis from the Phase 2 Optic Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (Cp-Cml) to Be Presented At the 2021 Asco Annual Meeting May 21
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo May 18
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma May 12
First quarter 2021 earnings released: EPS US$0.24 (vs US$3.33 loss in 1Q 2020) May 05
Incyte Corporation Provides Revenue Guidance for the Full Year 2021 May 05
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation Mar 19 Rendimenti per gli azionisti 0J9P GB Biotechs GB Mercato 7D -1.3% 2.0% 0.4% 1Y 3.4% -23.9% 3.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 0J9P ha superato il UK Biotechs che ha restituito -23.9 % nell'ultimo anno.
Rendimento vs Mercato: 0J9P ha eguagliato il mercato UK che ha restituito 3.9 % nell'ultimo anno.
Volatilità dei prezzi Is 0J9P's price volatile compared to industry and market? 0J9P volatility 0J9P Average Weekly Movement 5.8% Biotechs Industry Average Movement 9.8% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.3% 10% least volatile stocks in GB Market 2.6%
Prezzo delle azioni stabile: 0J9P non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di 0J9P è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1991 2,524 Herve Hoppenot www.incyte.com
Incyte Corporation, azienda biofarmaceutica, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di farmaci per l'ematologia/oncologia, l'infiammazione e l'autoimmunità negli Stati Uniti e a livello internazionale. L'azienda offre JAKAFI (ruxolitinib) per il trattamento della mielofibrosi a rischio intermedio o alto, della policitemia vera e della malattia acuta del trapianto contro l'ospite refrattaria agli steroidi; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) per il linfoma diffuso a grandi cellule B recidivato o refrattario; PEMAZYRE (pemigatinib), un inibitore della chinasi del recettore del fattore di crescita dei fibroblasti che agisce come driver oncogenico nei tumori liquidi e solidi; ICLUSIG (ponatinib) per il trattamento della leucemia mieloide cronica e della leucemia linfoblastica acuta positiva al cromosoma Philadelphia; ZYNYZ (retifanlimab-dlwr) per il trattamento di adulti con carcinoma a cellule di Merkel metastatico o recidivante localmente avanzato e OPZELURA crema per il trattamento della dermatite atopica. I suoi prodotti in fase clinica includono retifanlimab, in fase di sperimentazione clinica di Fase 3 per il carcinoma a cellule squamose del canale anale e per il carcinoma polmonare non a piccole cellule; axatilimab, un anticorpo monoclonale anti-CSF-1R in Fase 2 che viene sviluppato come terapia per i pazienti con GVHD cronica; INCA033989 per inibire l'oncogenesi; INCB160058, in fase di sviluppo come terapia modificante la malattia; e INCB99280 e INCB99318 per il trattamento dei tumori solidi.
Mostra di più Incyte Corporation Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Incyte con la sua capitalizzazione di mercato? 0J9P statistiche fondamentali Capitalizzazione di mercato US$13.31b Guadagni(TTM ) US$32.48m Ricavi(TTM ) US$4.08b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 0J9P Conto economico (TTM ) Ricavi US$4.08b Costo del fatturato US$2.88b Profitto lordo US$1.20b Altre spese US$1.16b Guadagni US$32.48m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 0.17 Margine lordo 29.33% Margine di profitto netto 0.80% Rapporto debito/patrimonio netto 0%
Come si è comportato 0J9P nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/02 07:46 Prezzo dell'azione a fine giornata 2024/12/31 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Incyte Corporation è coperta da 54 analisti. 23 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Jasper Hellweg Argus Research Company Thomas Russo Baird Ishan Majumdar Baptista Research
Mostra 51 altri analisti 
